Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan effects on right ventricular remodeling in pulmonary arterial hypertension
NL-OMON45109Phase 4Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change from baseline to Week 26 in right ventricular stroke volume and Week 26 to baseline pulmonary vascular resistance ratio. Started Jun 2015; status: active, not recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON45109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45109.